Evidence of comparative efficacy should have a formal role in European drug approvals
Publication
, Journal Article
Sorenson, C; Naci, H; Cylus, J; Mossialos, E
Published in: BMJ
September 6, 2011
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
BMJ
DOI
EISSN
1468-5833
ISSN
0959-8138
Publication Date
September 6, 2011
Volume
343
Issue
sep06 1
Start / End Page
d4849 / d4849
Publisher
BMJ
Related Subject Headings
- General & Internal Medicine
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Sorenson, C., Naci, H., Cylus, J., & Mossialos, E. (2011). Evidence of comparative efficacy should have a formal role in European drug approvals. BMJ, 343(sep06 1), d4849–d4849. https://doi.org/10.1136/bmj.d4849
Sorenson, C., H. Naci, J. Cylus, and E. Mossialos. “Evidence of comparative efficacy should have a formal role in European drug approvals.” BMJ 343, no. sep06 1 (September 6, 2011): d4849–d4849. https://doi.org/10.1136/bmj.d4849.
Sorenson C, Naci H, Cylus J, Mossialos E. Evidence of comparative efficacy should have a formal role in European drug approvals. BMJ. 2011 Sep 6;343(sep06 1):d4849–d4849.
Sorenson, C., et al. “Evidence of comparative efficacy should have a formal role in European drug approvals.” BMJ, vol. 343, no. sep06 1, BMJ, Sept. 2011, pp. d4849–d4849. Crossref, doi:10.1136/bmj.d4849.
Sorenson C, Naci H, Cylus J, Mossialos E. Evidence of comparative efficacy should have a formal role in European drug approvals. BMJ. BMJ; 2011 Sep 6;343(sep06 1):d4849–d4849.
Published In
BMJ
DOI
EISSN
1468-5833
ISSN
0959-8138
Publication Date
September 6, 2011
Volume
343
Issue
sep06 1
Start / End Page
d4849 / d4849
Publisher
BMJ
Related Subject Headings
- General & Internal Medicine
- 1117 Public Health and Health Services
- 1103 Clinical Sciences